Biotricity Inc. Liquidation Value

BTCY Medical Devices

Cash & Equivalents

$256,357
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $256,357
Total Obligations: -$24.34M
$-24.08M
Per share: $-0.87
Period: 2025-12-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $256,357
AR: $1.58M
Total Obligations: -$24.34M
$-22.50M
Per share: $-0.81
Period: 2025-12-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $256,357
AR: $1.58M
Inventory: $1.97M
Total Obligations: -$24.34M
$-20.53M
Per share: $-0.74
Period: 2025-12-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-24.08M$-0.87
Liquid Liquidation Value$-22.50M$-0.81
Operating Liquidation Value$-20.53M$-0.74

Key Components (as of 2025-12-31)

Data as of 2025-12-31 from 10-Q filed 2026-02-11. View on SEC EDGAR →

Cash & Equivalents$256,357
Accounts Receivable$1.58M
Inventory$1.97M
Current Liabilities$23.80M
Long-term Debt (?)N/A
Op. Lease Liability (?)$0
Finance Lease (?)N/A
Shares Outstanding27.8M

Explore all 128 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$256,357$1.58M$1.97MN/A$23.80MN/A$0N/A
2025-09-30$308,460$2.10M$2.26MN/A$23.61MN/A$102,307N/A
2025-06-30$391,292$1.86M$1.78MN/A$21.81MN/A$252,172N/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-Q 2026-02-11 View
2025-09-30 10-Q 2025-11-14 View
2025-06-30 10-Q 2025-08-14 View
2025-03-31 10-K/A 2025-07-18 View
2025-03-31 10-K 2025-07-15 View
2024-12-31 10-Q/A 2025-02-20 View
2024-12-31 10-Q 2025-02-19 View
2024-09-30 10-Q 2024-11-14 View

AI Insights

AI Insight·Generated 2026-05-06

Biotricity Inc. (BTCY) presents a deeply negative liquidation posture at December 31, 2025. MFFAIS-reported CLV is -$23.5M, LLV is -$22.0M, and OLV is -$20.0M, confirming that under any liquidation haircut scenario, equity recovers nothing and creditors absorb material losses. Total GAAP assets stand at $5.69M against total liabilities of $38.21M, producing book stockholders' equity of -$34.24M. The accumulated deficit is $142.1M. Under liquidation haircuts, the asset side deteriorates further: cash of $0.26M recovers 100% ($0.26M); AR current/noncurrent of $1.70M recovers roughly $1.53M-$1.60M at 90-95%; inventory of $1.97M recovers approximately $1.18M at 60%; PP&E net book value of $5K recovers negligibly; the ROU asset of $0.47M receives zero recovery value as it extinguishes with the lease; deposits of $1.28M in total may partially recover depending on counterparty (filed as $85K deposit plus other deposits). Total liquidation-adjusted assets are roughly $3.0M-$3.2M. Against this, liabilities at face value include: current convertible notes of $11.15M (dominant position), current loans payable $2.40M, accrued liabilities $3.73M, AP and other current $8.53M total current liabilities of $23.80M, plus noncurrent: long-term bank loans $12.13M, other long-term loans $0.87M, noncurrent derivative liabilities $1.41M, noncurrent ROU lease obligation $0 (fully current as of Dec 31, 2025), totaling $38.21M in liabilities. Liquidation deficit to equity holders is severe, approximately -$35M to -$38M. Mezzanine preferred (Series B, carrying value $1.71M) sits senior to common equity and would also be impaired in liquidation. Relative to the prior filing (September 30, 2025), the operating lease liability declined materially from $929K to $539K as the lease nears expiration (all remaining $565K undiscounted payments due in 2026, now fully classified as current). The derivative liability stack ($0.43M current + $1.41M noncurrent = $1.84M) remains a face-value liability in liquidation and is unchanged in gross terms QoQ. Convertible notes current at $11.15M represent the single largest liability; a subsequent event (February 2026) extended one note of $114K by 24 months, marginally reducing near-term pressure but immaterial to recovery. The going-concern qualification from the auditor remains active. Positive operating income of $997K for the nine-month period and positive EBITDA of $987K are income-statement items and do not directly affect liquidation recovery; the negative book equity and substantial debt stack dominate the liquidation analysis. Filing discusses preferred stock dividend accrual of $594K in the income statement but does not separately tag the accumulated preferred dividend balance in XBRL.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...